EXHIBIT 10.5.1 AMENDMENT NO. 1 RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT This Amendment No. 1 to Research, Development and Collaboration Agreement (the "Amendment No. 1") effective as of January 1, 1999, is entered into by and between GenVec,...Development and Collaboration Agreement • December 7th, 2000 • Genvec Inc • Pharmaceutical preparations
EX-10.11 15 a2238822zex-10_11.htm EX-10.11 HIGHLY CONFIDENTIAL EXECUTION VERSION [***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as...Development and Collaboration Agreement • May 5th, 2020
This Amendment No. 5 (this “Amendment No. 5”) to the Current Agreement (as defined below) is made as of January 22, 2018 (the “Amendment Effective Date”)
DEVELOPMENT AND COLLABORATION AGREEMENT by and between OTSUKA PHARMACEUTICAL CO., LTD. and ACUCELA INC. dated as of September 15, 2010Development and Collaboration Agreement • December 17th, 2013 • Acucela Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND COLLABORATION AGREEMENT (this “Agreement”) is made and entered into as of September 15, 2010 (the “Effective Date”) by and between OTSUKA PHARMACEUTICAL CO., LTD., a Japanese corporation having its principal place of business at Shinagawa Grand Central Tower, 2-16-4 Konan, Minato-Ku, Tokyo 108-8242, Japan (“Otsuka”), and ACUCELA INC., a Washington corporation having its principal place of business at 1301 Second Ave, Suite 1900, Seattle, Washington 98101-3805, USA (“Acucela”). Acucela and Otsuka are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
EXHIBIT 10.5 RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT WARNER-LAMBERT COMPANYDevelopment and Collaboration Agreement • December 7th, 2000 • Genvec Inc • Pharmaceutical preparations • Maryland
ContractDevelopment and Collaboration Agreement • May 28th, 2019 • Genmab a/S • Pharmaceutical preparations
[***] Certain information in this document, marked by brackets, has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K under the Securities Act of 1933, as amended, because it is both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.
SECRETED PROTEIN DEVELOPMENT AND COLLABORATION AGREEMENTDevelopment and Collaboration Agreement • March 29th, 2002 • Deltagen Inc • Services-commercial physical & biological research • California
SECRETED PROTEIN DEVELOPMENT AND COLLABORATION AGREEMENTDevelopment and Collaboration Agreement • August 9th, 2002 • Deltagen Inc • Services-commercial physical & biological research • California
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
JOINT VENTURE AGREEMENTDevelopment and Collaboration Agreement • May 29th, 2013 • Cloud Security Corp. • Services-advertising agencies • Nevada
JOINT VENTURE AGREEMENT (the “Agreement”), dated as of March 1, 2013 (the “Effective Date”) between Cloud Star Corp, a Nevada corporation with its principal place of business at 4590 MacArther Blvd., 5th Floor, Newport Beach, CA 92660 (“Cloud Star”), and App Ventures LTD, a Hong Kong private limited liability company with its principal place of business at 151 Gloucester Road, 11th Floor, Wanchai, Hong Kong (“App Ventures”).
AMENDMENT NO. 2 TO REVIVE AND AMEND THE DEVELOPMENT COLLABORATION AGREEMENTDevelopment and Collaboration Agreement • February 28th, 2022 • iRhythm Technologies, Inc. • Surgical & medical instruments & apparatus
This AMENDMENT NO. 2 TO REVIVE AND AMEND THE DEVELOPMENT AND COLLABORATION AGREEMENT (“Amendment”) is entered into by Verily Life Sciences LLC whose principal place of business is at 269 East Grand Avenue, South San Francisco, California 94080 USA (“VLS”), Verily Ireland Limited, organized under the laws of Ireland and having a principal place of business at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland (“VIL,” and together with VLS, “Verily”), and iRhythm Technologies, Inc., organized under the laws of Delaware and having a principal place of business at 699 8th Street, Suite 600, San Francisco, CA 94103 (“IRTC”).
SECOND AMENDMENT TO SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENTDevelopment and Collaboration Agreement • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations
This SECOND AMENDMENT TO SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT (“Second Amendment”) is entered into as of April 2, 2012 (“Second Amendment Effective Date”) by and between INTENDIS GMBH., a company organized under the laws of the Federal Republic of Germany (“Intendis”), and KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Kythera”).
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***]...Development and Collaboration Agreement • December 11th, 2012 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This MASTER PRODUCT DEVELOPMENT AND COLLABORATION AGREEMENT is made as of the 11th day of July 2011, by and among ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“ANI”), having a place of business at 210 Main Street West, Baudette, MN 56623 and RiconPharma LLC, a limited liability company having its principal office at 100 Ford Road, Suite #9, Denville, NJ 07834 (“RiconPharma”). ANI and RiconPharma may each be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDED AND RESTATED SECRETED PROTEIN DEVELOPMENT AND COLLABORATION AGREEMENT BETWEEN DELTAGEN, INC., AND NUVELO, INC.Development and Collaboration Agreement • May 10th, 2004 • Nuvelo Inc • In vitro & in vivo diagnostic substances
This Amended and Restated Secreted Protein Development and Collaboration Agreement (“Restated Agreement”) is made and entered into as of the Effective Date (defined below), by and between Deltagen, Inc., a Delaware corporation (hereinafter referred to as “Deltagen”), and Nuvelo, Inc., a Nevada corporation, as successor in interest to Hyseq, Inc. (hereinafter referred to as “Nuvelo”), with reference to the following facts and recitals. Deltagen and Nuvelo are referred to collectively hereinafter as the “Parties,” and individually as a “Party.”
SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENTDevelopment and Collaboration Agreement • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations • New York
THIS SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT (this “Collaboration Agreement”) is entered into as of August 26, 2010 (the “Effective Date”) by and between INTENDIS GMBH., a company organized under the laws of the Federal Republic of Germany (“Intendis”), and KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Kythera”). Kythera and Intendis are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***]...Development and Collaboration Agreement • January 18th, 2013 • Biosante Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
This MASTER PRODUCT DEVELOPMENT AND COLLABORATION AGREEMENT is made as of the 11th day of July 2011, by and among ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“ANI”), having a place of business at 210 Main Street West, Baudette, MN 56623 and RiconPharma LLC, a limited liability company having its principal office at 100 Ford Road, Suite #9, Denville, NJ 07834 (“RiconPharma”). ANI and RiconPharma may each be referred to herein individually as a “Party” and collectively as the “Parties.”
GLOBAL CO-DEVELOPMENT AND COLLABORATION AGREEMENT by and among BioAtla, LLC, BeiGene, Ltd. and BeiGene Switzerland GmbH Dated as of April 8, 2019Development and Collaboration Agreement • November 13th, 2020 • BioAtla, Inc. • Biological products, (no disgnostic substances) • New York
This Global Co-Development and Collaboration Agreement (this “Agreement”) is entered into as of April 8, 2019 (the “Effective Date”), by and among BioAtla, LLC, a Delaware limited liability company (“BioAtla”), BeiGene, Ltd., a Cayman Islands corporation (“BeiGene Cayman”) and BeiGene Switzerland GmbH, a company organized under the laws of Switzerland having an address of c/o VISCHER AG, Aeschenvorstadt 4, 4051 Basel, Switzerland (“BeiGene Switzerland” and together with BeiGene Cayman and its Affiliates, collectively, “BeiGene”). BeiGene and BioAtla are each referred to herein by name or as a “Party”, or, collectively, as the “Parties”.
FIRST AMENDMENT TO SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENTDevelopment and Collaboration Agreement • May 17th, 2012 • Kythera Biopharmaceuticals Inc • Pharmaceutical preparations
This FIRST AMENDMENT TO SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT (“First Amendment”) is entered into as of November 17,2010 (“First Amendment Effective Date”) by and between INTENDIS GMBH., a company organized under the Jaws of the Federal Republic of Germany (“Intendis”), and KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation (‘‘Kythera”).
RECITALSDevelopment and Collaboration Agreement • July 22nd, 2002 • Hyseq Inc • In vitro & in vivo diagnostic substances • California
